Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Srinivas Raghavan Viswanathan, M.D.,Ph.D.


Available: 01/02/23, Expires: 12/31/24

The Viswanathan lab uses cutting-edge genomic and genome-scale functional genetic technologies to dissect the molecular underpinnings and vulnerabilities of cancer, with a focus on genitourinary cancers (particularly cancers of the prostate and kidney). Several exciting opportunities are currently available for an HMS student. Some prior experience in a laboratory environment would be preferred to maximize the yield of the experience. Most projects have opportunities for both wet-lab and dry-lab (bioinformatics) involvement. Potential areas of research include the following: 1. Use of functional genetic (CRISPR) screening and large-scale mass spectrometry to identify new drug targets in castration-resistant prostate cancer. 2. Genetic and drug-screening of kidney cancer models in order to identify new therapies for rare and aggressive kidney cancer histologies. 3. Molecular biology and biochemistry studies to understand the basic mechanisms by which oncogenes in prostate and kidney cancers drive these diseases. 4. Analysis of whole genome and transcriptome sequencing data from patients with prostate and kidney cancers. Please see lab website: https://viswanathanlab.dana-farber.org/ for additional details.

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA286652 (VISWANATHAN, SRINIVAS RAGHAVAN) Sep 20, 2023 - Aug 31, 2028
    Probing the role of somatic X-chromosome alterations in shaping cancer sex differences
    Role: Principal Investigator
  2. R01CA279044 (VISWANATHAN, SRINIVAS RAGHAVAN) Aug 1, 2023 - Jul 31, 2028
    Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinoma
    Role: Principal Investigator
  3. R21CA263130 (MOUW, KENT W ;VISWANATHAN, SRINIVAS RAGHAVAN) Jul 1, 2021 - Jun 30, 2023
    Targeting the DNA Damage Response in CDK12-Mutant Prostate Cancer
    Role: Co-Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Viswanathan's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (192)
Co-Authors (75)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.